Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults

BACKGROUND: Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas. As it presents an excellent safety profile, we initiated a phase 1/2 clinical study of this anti-inflammatory drug for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Robe, Pierre A, Martin, Didier H, Nguyen-Khac, Minh T, Artesi, Maria, Deprez, Manuel, Albert, Adelin, Vanbelle, Sophie, Califice, Stephane, Bredel, Markus, Bours, Vincent
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771045/
https://www.ncbi.nlm.nih.gov/pubmed/19840379
http://dx.doi.org/10.1186/1471-2407-9-372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771045/
https://www.ncbi.nlm.nih.gov/pubmed/19840379
http://dx.doi.org/10.1186/1471-2407-9-372

Ejemplares similares